Adjuvant capecitabine and oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): a phase 3 open-label, randomised controlled trial.
By Y. Bang, Young-Woo Kim, Han-Kwang Yang, H. Chung, Young-Kyu Park, K. Lee, Keun-Wook Lee, Yong Ho Kim, S. Noh, J. Cho and 7 more. The Lancet, 2012
1,570 citations recorded by the source corpus.
Subfields: Gastroenterology, Pulmonary and Respiratory Medicine, Surgery
View Paper: https://www.semanticscholar.org/paper/5876809567b4dc52101ba203332fb9af8e64180b
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Gastroenterology
In Pulmonary and Respiratory Medicine
In Surgery
Citations in the corpus
- Gastric cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. (2010, methodology): “The CLASSIC trial evaluated a capecitabine–oxaliplatin doublet in a similar population and this was associated with significantly improved OS and disease-free survival (DFS) [50, 51] compared with surgery alone.”
- Japanese gastric cancer treatment guidelines 2018 (5th edition) (2020, neutral): “[66] Subsequently, oxaliplatin in the postoperative adjuvant”
- Japanese Gastric Cancer Treatment Guidelines 2021 (6th edition) (2022, result): “The CLASSIC trial conducted in Korea showed the prolongation of relapse-free survival of capecitabine plus oxaliplatin therapy (CapeOx) for TNM Stage II/III gastric cancer, and a study conducted in Japan confirmed its safety in Japanese patients [73].”
- Gastric cancer treatment: recent progress and future perspectives (2023, background): “The multi-center phase III CLASSIC trial undertaken in South Korea, China, and Taiwan compared upfront D2 surgery followed by CAPOX adjuvant chemotherapy versus D2 gastrectomy alone in patients with stage II-IIIB gastric cancer [26, 27].”